Oruka Therapeutics (NASDAQ:ORKA) Share Price Crosses Above Fifty Day Moving Average – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $89.99 and traded as high as $93.42. Oruka Therapeutics shares last traded at $90.33, with a volume of 1,942,731 shares trading hands.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 produced complete skin clearance in 61% of patients receiving the 600 mg dose at Week 16 in the ongoing EVERLAST-B Phase 2b trial, while 86% achieved PASI 90. The company said results were consistent with the earlier EVERLAST-A study and that safety and tolerability remained favorable. Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001
• Positive Sentiment: The strong efficacy profile prompted analysts and market commentators to describe the treatment as potentially transformative for psoriasis. Guggenheim reportedly estimated that ORKA-001 could generate as much as $7 billion in peak sales, increasing the perceived upside of Oruka’s pipeline. Guggenheim ORKA-001 Peak Sales Estimate
• Positive Sentiment: Oruka expects to begin Phase 3 development of ORKA-001 in the first half of 2027. Additional catalysts include 52-week EVERLAST-A results expected in December 2026 and ORKA-002 Phase 2 psoriasis results expected in the first quarter of 2027. Oruka Therapeutics Stock Gains on Positive Trial Results
• Neutral Sentiment: A report listed short interest at zero shares with a zero-day days-to-cover ratio, suggesting short positioning is not currently a meaningful trading factor, although the data may be incomplete or inconsistently reported.
• Negative Sentiment: Oruka remains a clinical-stage biotechnology company with no approved product, so valuation depends heavily on future trial results, regulatory progress and financing needs. Reported insider activity also showed sales without purchases, which may weigh on investor sentiment.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. UBS Group boosted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, September 24th. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.91.

Oruka Therapeutics Stock Performance

The business’s 50 day moving average price is $89.99 and its 200-day moving average price is $67.22. The company has a market cap of $5.98 billion, a price-to-earnings ratio of -44.50 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts expect that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares in the company, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 154,950 shares of company stock valued at $14,102,680 over the last quarter. Corporate insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nykredit A S bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $29,000. GAMMA Investing LLC grew its position in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after acquiring an additional 250 shares during the period. Orion Capital Management LLC bought a new stake in Oruka Therapeutics in the second quarter valued at $91,000. Sterling Capital Management LLC grew its position in Oruka Therapeutics by 839.0% in the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock valued at $138,000 after acquiring an additional 1,485 shares during the period. Finally, Natural Investments LLC acquired a new position in Oruka Therapeutics during the second quarter worth $202,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.